TOPaZ

Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid

TOPaZ is a randomised open-label clinical trial for people with osteogenesis imperfecta (OI). The study aims to investigate whether a two-year spell of treatment with a drug called teriparatide (TPTD) followed by treatment with another drug called Zoledronic acid (ZA) reduces the risk of broken bones occurring in people with OI.

Chief Investigator: Prof. Stuart Ralston

Number and location of participating sites (by region/ country): 25 UK, Republic of Ireland, France, Netherlands, Denmark

EudraCT number: 2016-003228-22

ISRCTN number: 15313991

Funder: NIHR Efficacy and Mechanism Evaluation Programme

Start and End date:

Of grant award - Nov 2016-April 2025

Of recruitment - Oct 2022

Current Status: In follow up

Trial Website: The TOPaZ Trial

UK GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with UK GDPR, please read this document.

ECTU TOPAZ UK GDPR privacy statement (78.9 KB PDF)

Sponsor: ACCORD http://www.accord.ed.ac.uk/

Chief Investigator: Professor Stuart Ralston, Molecular Medicine Centre, Institute of Genetics and Cancer, Western General Hospital, Edinburgh, EH4 2XU

Trial manager: topaz.trial@ed.ac.uk

ECTU Involvement: Trial management / Statistics / Database and randomisation service provision.

(UKCRC)